ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements with these filters
Sanjivani Paranteral received BSE in-principle approval for issuing 5,00,000 warrants to the promoter on a preferential basis, at not less than Rs 147.39 each. Listing is not yet approved and will follow allotment.
Sanjivani Paranteral Ltd reported revenue from operations of ₹25.3 Cr (+63.2% YoY) and net profit of ₹4.1 Cr (+156.2% YoY) for Q2 FY27.
Sanjivani Paranteral will hold a board meeting on 5 November 2026 to approve Q2 unaudited results. The agenda is only proposed until the meeting is held.
Sanjivani Paranteral Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI listing regulations.
Sanjivani Paranteral clarified the objects of its proposed 5 lakh convertible warrant issue to BSE. Proceeds of ~₹5.80 Cr will fund capex and subsidiary working capital for expansion.
Sanjivani Paranteral Limited held its 32nd Annual General Meeting on September 16, 2026. The meeting concluded with resolutions on financial statements and director re-appointment.
Sanjivani Paranteral Limited has filed its Annual Report for the financial year 2025-26 as required under SEBI regulations. The document details the company's annual performance.
Sanjivani Paranteral shareholders approved the issuance of 5,00,000 convertible warrants to promoters on a preferential basis. A material related party transaction with subsidiary SPL Infusion was also cleared.
Sanjivani Paranteral reported Q1 FY27 results, with total income of ₹23.99 Crore and a net profit of ₹2.49 Crore. The company demonstrated strong year-on-year growth across key metrics.
Sanjivani Paranteral Q1 FY27 consolidated revenue grew 33.8% YoY to ₹238.4 Mn, driven by the new Pune IV-fluid plant ramp-up. Transitioning to a multi-vertical platform with injectables, orals, and nutraceuticals.
Sanjivani Paranteral Ltd reported revenue from operations of ₹23.8 Cr (+33.0% YoY) and net profit of ₹2.5 Cr (+47.1% YoY) for Q1 FY27.
Sanjivani Paranteral Ltd has scheduled a board meeting for August 14, 2026, to consider quarterly financial results, the annual report, and the upcoming Annual General Meeting.
Sanjivani Paranteral Ltd issued a Postal Ballot notice to seek shareholder approval for issuing 5,00,000 convertible warrants and approving material related party transactions worth ₹10 Crore.
Sanjivani Paranteral issued a postal ballot notice to seek shareholder approval for issuing 5,00,000 convertible warrants to its promoter, raising ₹7.37 Crore.
Sanjivani Paranteral Ltd approved a preferential issue of 500,000 convertible warrants to Mr. Ashwani Khemka, raising ₹7.37 Crore. The issuance, set for an 18-month conversion window, strengthens capital.
Sanjivani Paranteral's board approved a preferential issue of 5,00,000 fully convertible warrants to a promoter. The issuance aggregates to ₹7.3695 Crore.
Sanjivani Paranteral Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI listing regulations.
Sanjivani Paranteral Limited scheduled a board meeting for July 23, 2026, to discuss a proposal for raising funds through warrants or convertible securities.
Promoter Ashwani Khemka bought 16,875 shares of Sanjivani Paranteral Ltd in the open market, raising his holding from 29.74% to 29.88%. Disclosure dated 25 June 2026.
Promoter Ashwani Khemka acquired 17,500 shares of Sanjivani Paranteral Limited through the open market. This transaction increases the promoter group's total stake to 29.74%.
Sanjivani Paranteral Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report notes prior governance non-compliances regarding board composition.
Sanjivani Paranteral's board appointed a valuer for a proposed preferential warrant issuance. This procedural step facilitates future fund-raising plans, pending further corporate and regulatory approvals.
Sanjivani Paranteral Q4 FY26 earnings transcript. Management transitions to a multi-vertical platform with base formulation business and new IVF and nutraceutical ventures.
Sanjivani Paranteral's Q4 & FY26 presentation shows significant decline in standalone financials. Focus remains on injectables (53.5% FY26 revenue) and export markets (78.5% FY26 revenue).
Sanjivani Paranteral Ltd reported revenue from operations of ₹13.2 Cr (-27.5% YoY) and net profit of ₹0.5 Cr (-77.3% YoY) for Q4 FY26.
Sanjivani Paranteral approved FY26 audited financial results. The company reported standalone net profit of ₹6.92 Crore, showing operational stability despite geopolitical logistics challenges.
Sanjivani Paranteral Limited has scheduled a Board Meeting for May 14, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's trading window remains closed until 48 hours after the results announcement.
Sanjivani Paranteral Limited (BSE: 531569) issued an initial disclosure for FY 2026-27 confirming it is not identified as a 'Large Corporate' under SEBI norms. The company reported zero outstanding borrowings as of March 31, 2026.
Sanjivani Paranteral Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the period ending March 31, 2026. The Registrar and Transfer Agent, MUFG Intime India, confirmed that no dematerialisation requests were received during the quarter. This is a routine regulatory filing with no material impact on operations.